US 12,103,958 B2
Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions
Natasha Kay Crellin, New York, NY (US); Lauren Kate Ely, New York, NY (US); Jason Robles Reyes, New York, NY (US); Chia Chi Ho, New York, NY (US); Jeffrey A. Bluestone, Oakland, CA (US); Eleonora Trotta, Oakland, CA (US); and Qizhi Tang, Oakland, CA (US)
Assigned to Pfizer Inc., New York, NY (US); and The Regents of the University of California, Oakland, CA (US)
Filed by PFIZER INC., New York, NY (US); and THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed on Sep. 28, 2020, as Appl. No. 17/035,327.
Application 17/035,327 is a continuation of application No. PCT/US2019/023883, filed on Mar. 25, 2019.
Claims priority of provisional application 62/783,986, filed on Dec. 21, 2018.
Claims priority of provisional application 62/650,022, filed on Mar. 29, 2018.
Prior Publication US 2021/0032308 A1, Feb. 4, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); C12N 15/63 (2006.01); G01N 33/50 (2006.01); G01N 33/68 (2006.01)
CPC C07K 14/70528 (2013.01) [A61K 39/001129 (2018.08); C12N 15/63 (2013.01); G01N 33/505 (2013.01); G01N 33/68 (2013.01); C07K 2319/30 (2013.01); G01N 2333/70507 (2013.01)] 16 Claims
 
1. An isolated polypeptide molecule that specifically binds to CD2,
wherein the polypeptide molecule comprises an amino acid sequence having at least about 95% identity to the amino acid sequence of SEQ ID NO: 69, and wherein the polypeptide molecule consists of one or more substitutions at residues 36, 38, 43, 45, 77, and 86 relative to SEQ ID NO: 3, numbered according to SEQ ID NO: 3.